OR Royalties Inc. (NYSE:OR) Receives $46.50 Consensus Target Price from Brokerages

Shares of OR Royalties Inc. (NYSE:OR) have been given an average rating of “Moderate Buy” by the ten analysts that are currently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $46.50.

Several brokerages recently commented on OR. Wall Street Zen downgraded shares of OR Royalties from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Weiss Ratings reiterated a “buy (b)” rating on shares of OR Royalties in a research note on Monday, December 29th. Royal Bank Of Canada reiterated an “outperform” rating and set a $56.00 target price on shares of OR Royalties in a research note on Friday, April 10th. Scotiabank increased their target price on OR Royalties from $41.00 to $51.00 and gave the company a “sector perform” rating in a research note on Monday, January 26th. Finally, TD Securities reiterated a “hold” rating on shares of OR Royalties in a research note on Monday, February 23rd.

OR Royalties Stock Up 0.2%

OR Royalties stock opened at $42.69 on Friday. The company has a market capitalization of $8.00 billion, a P/E ratio of 39.17 and a beta of 0.83. The stock’s 50 day moving average is $40.89 and its 200 day moving average is $38.17. OR Royalties has a twelve month low of $22.08 and a twelve month high of $48.06.

OR Royalties (NYSE:OR) last posted its quarterly earnings results on Wednesday, February 18th. The basic materials company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.01. OR Royalties had a return on equity of 12.41% and a net margin of 74.30%.The company had revenue of $90.47 million for the quarter, compared to the consensus estimate of $90.80 million. As a group, equities analysts expect that OR Royalties will post 0.62 EPS for the current year.

OR Royalties Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Tuesday, March 31st were issued a dividend of $0.055 per share. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Tuesday, March 31st. OR Royalties’s dividend payout ratio (DPR) is presently 20.18%.

Institutional Trading of OR Royalties

A number of institutional investors have recently made changes to their positions in OR. Linden Thomas Advisory Services LLC boosted its stake in shares of OR Royalties by 4.1% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 6,254 shares of the basic materials company’s stock worth $221,000 after buying an additional 249 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of OR Royalties by 6.2% in the 4th quarter. Wells Fargo & Company MN now owns 5,901 shares of the basic materials company’s stock worth $209,000 after buying an additional 346 shares during the last quarter. Allworth Financial LP boosted its stake in shares of OR Royalties by 20.0% in the 4th quarter. Allworth Financial LP now owns 2,305 shares of the basic materials company’s stock worth $82,000 after buying an additional 384 shares during the last quarter. Cetera Investment Advisers boosted its stake in shares of OR Royalties by 3.5% in the 2nd quarter. Cetera Investment Advisers now owns 13,147 shares of the basic materials company’s stock worth $337,000 after buying an additional 440 shares during the last quarter. Finally, FIL Ltd purchased a new position in shares of OR Royalties in the 4th quarter worth $29,000. Hedge funds and other institutional investors own 68.52% of the company’s stock.

OR Royalties Company Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.